Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that focuses on a variety of ailments involving the neurological, cardiovascular, and other ailments. The firm is focused on developing weight loss drugs that enable users to retain lean muscle mass while shedding weight. Over the year, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s shares are up by 16.32%, and since Cramer discussed the firm in March 2025, they are up by 10.6%. The stock closed 11.8% higher on October 28th as the firm reported its third-quarter earnings report. The results saw the firm post $3.75 billion in revenue and $11.83 in quarterly profit per share to beat analyst estimates of $3.59 billion and $9.59. Year-to-date, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s shares are down by 4.9%. A notable dip came in January when the shares dipped significantly between the 9th and 16th. Bank of America discussed the firm in January as it bumped Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s rat
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- NTLA Stock Rises 20% in 3 Months: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What's Next [Yahoo! Finance]Yahoo! Finance
- Regeneron and Telix Announce Strategic Radiopharma CollaborationGlobeNewswire
- Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)GlobeNewswire
- Telix and Regeneron Announce Strategic Radiopharma CollaborationPR Newswire
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 4/8/26 - Form 8-K
- 4/3/26 - Form 4
- 3/27/26 - Form SCHEDULE
- REGN's page on the SEC website